Review

human tnbc cell lines mda mb 231 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC human tnbc cell lines mda mb 231
Human Tnbc Cell Lines Mda Mb 231, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 24425 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnbc+cell+lines/pmc13266114-183-1-6?v=ATCC
Average 99 stars, based on 24425 article reviews

human tnbc cell lines mda mb 231 - by Bioz Stars, 2026-08

99/100 stars

Images

Image Search Results

CEP exerts cytotoxicity in TNBC cells. (A) Chemical structure of CEP. (B) CEP inhibited TNBC cell viability. The effect of CEP treatment on TNBC cell viability after 24, 48 and 72 h. (C) CEP inhibited clonogenicity of MDA-MB-231 and Hs578T cells. n=3; *P < 0.05, **P < 0.01 and ***P < 0.001 vs. control. CEP, cepharanthine; TNBC, triple-negative breast cancer.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP exerts cytotoxicity in TNBC cells. (A) Chemical structure of CEP. (B) CEP inhibited TNBC cell viability. The effect of CEP treatment on TNBC cell viability after 24, 48 and 72 h. (C) CEP inhibited clonogenicity of MDA-MB-231 and Hs578T cells. n=3; *P < 0.05, **P < 0.01 and ***P < 0.001 vs. control. CEP, cepharanthine; TNBC, triple-negative breast cancer.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Control

CEP induces apoptosis in triple-negative breast cancer cells. Flow cytometric quantification of apoptosis induced by CEP in (A) MDA-MB-231 and (B) Hs578T cells (n=3; 48 h). **P<0.01 and ***P < 0.001 vs. control. CEP, cepharanthine; ns, not significant.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP induces apoptosis in triple-negative breast cancer cells. Flow cytometric quantification of apoptosis induced by CEP in (A) MDA-MB-231 and (B) Hs578T cells (n=3; 48 h). **P<0.01 and ***P < 0.001 vs. control. CEP, cepharanthine; ns, not significant.

Techniques: Control

CEP induces ΔΨm loss in triple-negative breast cancer cells. (A) MDA-MB-231 (10 µM; n=3; 24 h) and (B) Hs578T cells (4 µM; n=3; 24 h). Scale bar, 100 µM. CEP, cepharanthine.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP induces ΔΨm loss in triple-negative breast cancer cells. (A) MDA-MB-231 (10 µM; n=3; 24 h) and (B) Hs578T cells (4 µM; n=3; 24 h). Scale bar, 100 µM. CEP, cepharanthine.

Techniques:

CEP upregulates NOXA and downregulates Bcl-2 expression in triple-negative breast cancer cells. CEP upregulated NOXA and downregulated Bcl-2 expression in (A) MDA-MB-231 cells (n=3; 24 h) and (B) Hs578T cells (n=3; 24 h). *P<0.05, **P<0.01 and ***P<0.001 vs. control. CEP, cepharanthine; NOXA, phorbol-12-myristate-13-acetate-induced protein 1; ns, not significant.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP upregulates NOXA and downregulates Bcl-2 expression in triple-negative breast cancer cells. CEP upregulated NOXA and downregulated Bcl-2 expression in (A) MDA-MB-231 cells (n=3; 24 h) and (B) Hs578T cells (n=3; 24 h). *P<0.05, **P<0.01 and ***P<0.001 vs. control. CEP, cepharanthine; NOXA, phorbol-12-myristate-13-acetate-induced protein 1; ns, not significant.

Techniques: Expressing, Control

Proteomic profiling of MDA-MB-231 cells following CEP treatment. (A) The 20 most significantly downregulated Gene Ontology cellular components with CEP treatment. (B) Significantly downregulated Kyoto Encyclopedia of Genes and Genomes pathways with CEP treatment. CEP, cepharanthine.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: Proteomic profiling of MDA-MB-231 cells following CEP treatment. (A) The 20 most significantly downregulated Gene Ontology cellular components with CEP treatment. (B) Significantly downregulated Kyoto Encyclopedia of Genes and Genomes pathways with CEP treatment. CEP, cepharanthine.

Techniques:

CEP treatment activates TFEB in triple-negative breast cancer cells. (A) CEP triggers TFEB nuclear translocation in MDA-MB-231 cells (10 µM; 24 h). (B) CEP triggers TFEB nuclear translocation in Hs578T cells (4 µM; 24 h). Scale bar, 25 µm; n=5. **P<0.01 vs. control. TFEB, transcription factor EB; CEP, cepharanthine.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP treatment activates TFEB in triple-negative breast cancer cells. (A) CEP triggers TFEB nuclear translocation in MDA-MB-231 cells (10 µM; 24 h). (B) CEP triggers TFEB nuclear translocation in Hs578T cells (4 µM; 24 h). Scale bar, 25 µm; n=5. **P<0.01 vs. control. TFEB, transcription factor EB; CEP, cepharanthine.

Techniques: Translocation Assay, Control

CEP does not induce LMP, increase lysosomal pH or destabilize lysosomal membrane-bound enzymes in triple-negative breast cancer cells. (A) CEP does not induce LMP, as evidenced by a dispersion of dextran, in MDA-MB-231 (10 µM; 24 h) and Hs578T cells (4 µM; 24 h). Scale bar, 25 µm. (B) CEP does not elevate lysosomal pH in the MDA-MB-231 (10 µM; 24 h) and Hs578T cell lines (4 µM; 24 h). Scale bar, 25 µm. (C) CEP does not induce lysosomal membrane-bound enzymes degradation in the MDA-MB-231 (10 µM; n=3; 24 h) and Hs578T cell lines (4 µM; n=3; 24 h). CEP, cepharanthine; ASAH1, acid ceramidase; SMPD1, sphingomyelin phosphodiesterase; ns, not significant.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP does not induce LMP, increase lysosomal pH or destabilize lysosomal membrane-bound enzymes in triple-negative breast cancer cells. (A) CEP does not induce LMP, as evidenced by a dispersion of dextran, in MDA-MB-231 (10 µM; 24 h) and Hs578T cells (4 µM; 24 h). Scale bar, 25 µm. (B) CEP does not elevate lysosomal pH in the MDA-MB-231 (10 µM; 24 h) and Hs578T cell lines (4 µM; 24 h). Scale bar, 25 µm. (C) CEP does not induce lysosomal membrane-bound enzymes degradation in the MDA-MB-231 (10 µM; n=3; 24 h) and Hs578T cell lines (4 µM; n=3; 24 h). CEP, cepharanthine; ASAH1, acid ceramidase; SMPD1, sphingomyelin phosphodiesterase; ns, not significant.

Techniques: Membrane, Dispersion

CEP binds to and inhibits lysosomal enzymes. (A) Structurally altered peptides in the MDA-MB-231 cell line upon CEP treatment (10 µM, 1 h; FC >1.5 or <0.667, false discovery rate <1, P<0.01; n=3). (B) CEP treatment suppresses the maturation of CTSB and CTSD (24 h). *P<0.05, **P<0.01 and ***P<0.001 vs. control. CEP, cepharanthine; FC, fold change; CTSD, cathepsin D; CTSB, cathepsin B; pro-CTSB pro-cathepsin B; pro-CTSD, pro-cathepsin D; i-CTSB, inactive cathepsin B; m-CTSB, mature cathepsin B; m-CTSD, mature cathepsin D.

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP binds to and inhibits lysosomal enzymes. (A) Structurally altered peptides in the MDA-MB-231 cell line upon CEP treatment (10 µM, 1 h; FC >1.5 or <0.667, false discovery rate <1, P<0.01; n=3). (B) CEP treatment suppresses the maturation of CTSB and CTSD (24 h). *P<0.05, **P<0.01 and ***P<0.001 vs. control. CEP, cepharanthine; FC, fold change; CTSD, cathepsin D; CTSB, cathepsin B; pro-CTSB pro-cathepsin B; pro-CTSD, pro-cathepsin D; i-CTSB, inactive cathepsin B; m-CTSB, mature cathepsin B; m-CTSD, mature cathepsin D.

Techniques: Control

Combination therapy with docetaxel and mSTAR1302 elicits antitumor effects in triple negative breast cancer (4T1) and androgen-independent prostate cancer (TRAMP-C2) mouse models. (A–E) 8–12-week-old female Balb/c mice were inoculated subcutaneously with 5x10 4 4T1 in the mammary fat pad (n=8–10 per group). (A) pictogram depicts experimental design. When the tumors reached 40-70mm 3 , mice were administered 3 doses of mSTAR1302 (1 mg/kg, i.p.) once per week on days 9, 16, and 23 and 3 doses of docetaxel (500 µg, i.p.), every other day, 7 days post-initial mSTAR1302 treatment, on days 16, 18, and 20. Primary tumors were measured in terms of mean (B) and individual (C) tumor volumes, as depicted. Inset numbers are tumor-free mice. In two additional cohorts, to assess metastatic growth, lungs were removed from 4T1 tumor-bearing mice 28 days post-tumor inoculation following the same treatment schedule. Lungs were dissociated, cultured in medium (2x FBS with 6-thioguanine) and incubated at 37 °C with 5% CO 2 for 12 days. (D) a meta-analysis from two separate studies is depicted with closed and opened circles differentiating data collected from each study. Cell colonies representing lung metastases were stained with 0.05% methylene blue and counted for each treatment group (n=14–20 per group total). Survival (E) was measured over time with inset numbers depicting median overall survival (mOS) and shaded bands depicting 95% confidence intervals. (F–I) 8–12-week-old male C57bl/6 mice were inoculated subcutaneously with 2.5x10 6 TRAMP-C2, on the right flank (n=8–10 per group). (F) pictogram depicts experimental design. Mice were administered mSTAR1302 (1 mg/kg, i.p.) when tumors reached 70–100mm 3 on days 22, 29, and 36, and docetaxel (500 µg, i.p.) on days 29, 31, and 33. Tumors were measured with mean (G) and individual (H) tumor volumes depicted. Inset numbers are tumor-free mice. Survival (I) was measured over time with mOS and 95% confidence intervals (shaded bands) depicted. Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test; comparison between groups: one-way ANOVA with Tukey’s post hoc test; survival; Mantel-Cox test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; FBS, fetal bovine serum; i.p., intraperitoneal; mets, metastases; s.c., subcutaneously.

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Combination therapy with docetaxel and mSTAR1302 elicits antitumor effects in triple negative breast cancer (4T1) and androgen-independent prostate cancer (TRAMP-C2) mouse models. (A–E) 8–12-week-old female Balb/c mice were inoculated subcutaneously with 5x10 4 4T1 in the mammary fat pad (n=8–10 per group). (A) pictogram depicts experimental design. When the tumors reached 40-70mm 3 , mice were administered 3 doses of mSTAR1302 (1 mg/kg, i.p.) once per week on days 9, 16, and 23 and 3 doses of docetaxel (500 µg, i.p.), every other day, 7 days post-initial mSTAR1302 treatment, on days 16, 18, and 20. Primary tumors were measured in terms of mean (B) and individual (C) tumor volumes, as depicted. Inset numbers are tumor-free mice. In two additional cohorts, to assess metastatic growth, lungs were removed from 4T1 tumor-bearing mice 28 days post-tumor inoculation following the same treatment schedule. Lungs were dissociated, cultured in medium (2x FBS with 6-thioguanine) and incubated at 37 °C with 5% CO 2 for 12 days. (D) a meta-analysis from two separate studies is depicted with closed and opened circles differentiating data collected from each study. Cell colonies representing lung metastases were stained with 0.05% methylene blue and counted for each treatment group (n=14–20 per group total). Survival (E) was measured over time with inset numbers depicting median overall survival (mOS) and shaded bands depicting 95% confidence intervals. (F–I) 8–12-week-old male C57bl/6 mice were inoculated subcutaneously with 2.5x10 6 TRAMP-C2, on the right flank (n=8–10 per group). (F) pictogram depicts experimental design. Mice were administered mSTAR1302 (1 mg/kg, i.p.) when tumors reached 70–100mm 3 on days 22, 29, and 36, and docetaxel (500 µg, i.p.) on days 29, 31, and 33. Tumors were measured with mean (G) and individual (H) tumor volumes depicted. Inset numbers are tumor-free mice. Survival (I) was measured over time with mOS and 95% confidence intervals (shaded bands) depicted. Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test; comparison between groups: one-way ANOVA with Tukey’s post hoc test; survival; Mantel-Cox test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; FBS, fetal bovine serum; i.p., intraperitoneal; mets, metastases; s.c., subcutaneously.

Article Snippet: The murine TNBC cell line 4T1 and androgen-independent prostate cell line TRAMP-C2 were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured according to ATCC recommendations.

Techniques: Cell Culture, Incubation, Staining, Comparison

Docetaxel induces upregulation of death receptors TRAIL-R2 and FAS in 4T1 and TRAMP-C2 cells. (A) 4T1 and TRAMP-C2 cells were treated in vitro with either no drug or docetaxel (250 ng/mL) for 48 hours and analyzed for surface expression of FAS and TRAIL-R2 via flow cytometry. Histograms indicating frequency and gMFI are shown. Experiment repeated twice with similar results. (B) 4T1 and TRAMP-C2 cells were treated as described in <xref ref-type=

Figure 1A and then co-cultured with TRAIL ligand or FAS ligand and protein G and measured for relative cell lysis compared to cells alone. (C, D) tumors harvested on day 28, after treatment as described in Figure 1A , were fixed for multiplex immunofluorescence staining and quantified for CD8 (green) and TRAIL-R2 or FAS (red) expression. (E) differential gene expression was interrogated using NanoString murine PanCancer immune profiling panel on tumors harvested on day 23 from 4T1 tumor-bearing Balb/c female mice, following treatment as previously described. Fold change compared to untreated tumors reported for TRAIL and FAS ligands. (F) 4T1 cells were exposed to docetaxel (250 ng/mL) for 48 hours and co-cultured with NK cells isolated from tumor-free Balb/c mice (E:T = 25:1) and monitored for relative NK-specific lysis of tumor cells for up to 8 hours post-effector addition. Statistical tests: comparison between groups: One-way ANOVA with Tukey’s post hoc test. comparison between two groups: unpaired T-test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; FoV, field of view; gMFI, geometric mean fluorescence intensity; NK, natural killer. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Docetaxel induces upregulation of death receptors TRAIL-R2 and FAS in 4T1 and TRAMP-C2 cells. (A) 4T1 and TRAMP-C2 cells were treated in vitro with either no drug or docetaxel (250 ng/mL) for 48 hours and analyzed for surface expression of FAS and TRAIL-R2 via flow cytometry. Histograms indicating frequency and gMFI are shown. Experiment repeated twice with similar results. (B) 4T1 and TRAMP-C2 cells were treated as described in Figure 1A and then co-cultured with TRAIL ligand or FAS ligand and protein G and measured for relative cell lysis compared to cells alone. (C, D) tumors harvested on day 28, after treatment as described in Figure 1A , were fixed for multiplex immunofluorescence staining and quantified for CD8 (green) and TRAIL-R2 or FAS (red) expression. (E) differential gene expression was interrogated using NanoString murine PanCancer immune profiling panel on tumors harvested on day 23 from 4T1 tumor-bearing Balb/c female mice, following treatment as previously described. Fold change compared to untreated tumors reported for TRAIL and FAS ligands. (F) 4T1 cells were exposed to docetaxel (250 ng/mL) for 48 hours and co-cultured with NK cells isolated from tumor-free Balb/c mice (E:T = 25:1) and monitored for relative NK-specific lysis of tumor cells for up to 8 hours post-effector addition. Statistical tests: comparison between groups: One-way ANOVA with Tukey’s post hoc test. comparison between two groups: unpaired T-test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; FoV, field of view; gMFI, geometric mean fluorescence intensity; NK, natural killer.

Techniques: In Vitro, Expressing, Flow Cytometry, Cell Culture, Lysis, Multiplex Assay, Immunofluorescence, Staining, Gene Expression, Isolation, Comparison, Fluorescence

Antitumor activity of docetaxel and mSTAR1302 attenuated in TRAIL-R2 knockdown tumor mouse models. (A) TRAIL-R2 was knocked down via CRISPR in TRAMP-C2 and 4T1 cell lines. Flow cytometry was used to confirm expression in clones and WT cell lines. (B) 8–12-week-old male C57bl/6 mice were implanted with 2.5x10 6 TRAMP-C2 (n=10–12 per group) or TRAMP-C2 TRAIL-KO (n=7–9 per group) cells in the right flank. Treatment schedules for each group are depicted. Mean tumor volumes graphed. (C) 8–12-week-old female Balb/c mice were implanted with 5x10 4 4T1 (n=18–20 per group) or 4T1 TRAIL KO cells (n=10) in the mammary fat pad. WT 4T1 mice from this study were assessed concurrently in the study from <xref ref-type=

Figure 7 and mean tumor volumes displayed in Figure 7C are the same tumor volumes displayed in Figure 7B . Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. WT, wild type; KO, knockouts; CRISPR, clustered regularly interspaced short palindromic repeats; i.p., intraperitoneal; s.c., subcutaneously; ns, not significant. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Antitumor activity of docetaxel and mSTAR1302 attenuated in TRAIL-R2 knockdown tumor mouse models. (A) TRAIL-R2 was knocked down via CRISPR in TRAMP-C2 and 4T1 cell lines. Flow cytometry was used to confirm expression in clones and WT cell lines. (B) 8–12-week-old male C57bl/6 mice were implanted with 2.5x10 6 TRAMP-C2 (n=10–12 per group) or TRAMP-C2 TRAIL-KO (n=7–9 per group) cells in the right flank. Treatment schedules for each group are depicted. Mean tumor volumes graphed. (C) 8–12-week-old female Balb/c mice were implanted with 5x10 4 4T1 (n=18–20 per group) or 4T1 TRAIL KO cells (n=10) in the mammary fat pad. WT 4T1 mice from this study were assessed concurrently in the study from Figure 7 and mean tumor volumes displayed in Figure 7C are the same tumor volumes displayed in Figure 7B . Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. WT, wild type; KO, knockouts; CRISPR, clustered regularly interspaced short palindromic repeats; i.p., intraperitoneal; s.c., subcutaneously; ns, not significant.

Techniques: Activity Assay, Knockdown, CRISPR, Flow Cytometry, Expressing, Clone Assay

Co-treatment of 4T1 tumors with docetaxel and mSTAR1302 enhances tumor-infiltrating lymphocytes. RNA was isolated from tumors collected on day 23 from 4T1 tumor-bearing Balb/c female mice, following treatment, as previously described in <xref ref-type=

Figure 1A . RNA analysis performed via NanoString murine PanCancer immune profiling panel. Heatmaps displaying (A) the top 10 differentially upregulated and downregulated genes by fold change for treatment groups compared to control, weighted by combination, and (B) a cell profiling analysis normalized via an abundance score. DC, dendritic cells; NK, natural killer cells; Th1, T helper 1 cells; Tregs, regulatory T cells. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Co-treatment of 4T1 tumors with docetaxel and mSTAR1302 enhances tumor-infiltrating lymphocytes. RNA was isolated from tumors collected on day 23 from 4T1 tumor-bearing Balb/c female mice, following treatment, as previously described in Figure 1A . RNA analysis performed via NanoString murine PanCancer immune profiling panel. Heatmaps displaying (A) the top 10 differentially upregulated and downregulated genes by fold change for treatment groups compared to control, weighted by combination, and (B) a cell profiling analysis normalized via an abundance score. DC, dendritic cells; NK, natural killer cells; Th1, T helper 1 cells; Tregs, regulatory T cells.

Techniques: Isolation, Control

Vβ13 T cells are upregulated with docetaxel and mSTAR1302 combination treatment in 4T1 triple negative breast cancer model. Balb/c mice were inoculated with 4T1 cells on day 0 and treated with mSTAR1302 and docetaxel as previously described in <xref ref-type=

Figure 1A . Tumors were harvested, processed, and stained on day 23. Flow cytometry was performed to determine the frequency of (A) CD4 and (B) CD8 T cells, which were further analyzed for expression of Vβ13 (Vβ8.1), (C) Tregs, (D) NK cells, (E) MDSCs, and (F) macrophages, which were further analyzed to determine M1, M2, and M1:M2 status. Statistical tests: comparison between groups: one-way ANOVA with Tukey’s post hoc test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; MDSCs, myeloid-derived suppressor cells; NK, natural killer cells; Tregs, regulatory T cells. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Vβ13 T cells are upregulated with docetaxel and mSTAR1302 combination treatment in 4T1 triple negative breast cancer model. Balb/c mice were inoculated with 4T1 cells on day 0 and treated with mSTAR1302 and docetaxel as previously described in Figure 1A . Tumors were harvested, processed, and stained on day 23. Flow cytometry was performed to determine the frequency of (A) CD4 and (B) CD8 T cells, which were further analyzed for expression of Vβ13 (Vβ8.1), (C) Tregs, (D) NK cells, (E) MDSCs, and (F) macrophages, which were further analyzed to determine M1, M2, and M1:M2 status. Statistical tests: comparison between groups: one-way ANOVA with Tukey’s post hoc test. Error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; MDSCs, myeloid-derived suppressor cells; NK, natural killer cells; Tregs, regulatory T cells.

Techniques: Staining, Flow Cytometry, Expressing, Comparison, Derivative Assay

Docetaxel and mSTAR1302 antitumor immune response dependent on CD4+ T, CD8+ T, and NK cell activity. Female Balb/c mice were implanted with 4T1 tumors and treated as described in <xref ref-type=

Figure 1A with docetaxel and mSTAR1302. (B, D, H) anti-CD4 (100 μg, i.p.) and (C, D, H) anti-CD8 depleting antibodies were administered on days 6, 7, and 8, post-tumor implantation and then once every 7 days thereafter. (E) an anti-Vβ13 (1 mg/kg, i.p.) depleting antibody was administered on days 6 and 8, and every 7 days thereafter. (F) anti-IFN-γ (100 μg, i.p.) was administered 2 days prior to, the same day as, and 2 days following mSTAR1302 treatment (i.e., days 7, 9, 11, 14, 16, 18, 21, 23, and 25). (G, H) anti-NK–depleting antibody (25 µl in 100 µl of PBS, i.p.) was administered on days 5 and 7 and then every 5 days subsequently. (A–H) mean tumor volume displayed. Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test; error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; anti, antibody; IFN-γ, interferon gamma; i.p., intraperitoneal; ns, not significant; NK, natural killer. " width="100%" height="100%">

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Docetaxel and mSTAR1302 antitumor immune response dependent on CD4+ T, CD8+ T, and NK cell activity. Female Balb/c mice were implanted with 4T1 tumors and treated as described in Figure 1A with docetaxel and mSTAR1302. (B, D, H) anti-CD4 (100 μg, i.p.) and (C, D, H) anti-CD8 depleting antibodies were administered on days 6, 7, and 8, post-tumor implantation and then once every 7 days thereafter. (E) an anti-Vβ13 (1 mg/kg, i.p.) depleting antibody was administered on days 6 and 8, and every 7 days thereafter. (F) anti-IFN-γ (100 μg, i.p.) was administered 2 days prior to, the same day as, and 2 days following mSTAR1302 treatment (i.e., days 7, 9, 11, 14, 16, 18, 21, 23, and 25). (G, H) anti-NK–depleting antibody (25 µl in 100 µl of PBS, i.p.) was administered on days 5 and 7 and then every 5 days subsequently. (A–H) mean tumor volume displayed. Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test; error bars, SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; anti, antibody; IFN-γ, interferon gamma; i.p., intraperitoneal; ns, not significant; NK, natural killer.

Techniques: Activity Assay, Tumor Implantation

Docetaxel and mSTAR1302 co-treatment promote antigen-specific T cells in the 4T1 tumor model. Female Balb/c 4T1 tumor-bearing mice were treated with mSTAR1302 and docetaxel as previously described (n=20/group). (A) pictogram depicts experimental design. (B) mean and individual tumor volumes recorded over time. On day 23, the spleens of 8 mice per group were surgically excised and processed. Splenocytes were plated on ELISPOT plates coated with IFN-γ–specific capture antibody and co-cultured with AH1 peptide, CD3/CD28 antibody as a positive control, or β-gal overnight, then developed with detection antibody. β-gal was used to normalize data to account for non-specific binding and background. ELISPOT plates were pictured (C) and quantified (D) for total number of spots. Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test. Comparison between groups: one-way ANOVA with Tukey’s post hoc test. Error bars, SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; IFN-γ, interferon gamma; i.p., intraperitoneal; s.c., subcutaneously; SFC, spot-forming cells.

Journal: Frontiers in Immunology

Article Title: Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models

doi: 10.3389/fimmu.2026.1850760

Figure Lengend Snippet: Docetaxel and mSTAR1302 co-treatment promote antigen-specific T cells in the 4T1 tumor model. Female Balb/c 4T1 tumor-bearing mice were treated with mSTAR1302 and docetaxel as previously described (n=20/group). (A) pictogram depicts experimental design. (B) mean and individual tumor volumes recorded over time. On day 23, the spleens of 8 mice per group were surgically excised and processed. Splenocytes were plated on ELISPOT plates coated with IFN-γ–specific capture antibody and co-cultured with AH1 peptide, CD3/CD28 antibody as a positive control, or β-gal overnight, then developed with detection antibody. β-gal was used to normalize data to account for non-specific binding and background. ELISPOT plates were pictured (C) and quantified (D) for total number of spots. Statistical tests: tumor growth: two-way ANOVA with Tukey’s post hoc test. Comparison between groups: one-way ANOVA with Tukey’s post hoc test. Error bars, SEM. *p < 0.05, ***p < 0.001, ****p < 0.0001. ANOVA, analysis of variance; IFN-γ, interferon gamma; i.p., intraperitoneal; s.c., subcutaneously; SFC, spot-forming cells.

Techniques: Enzyme-linked Immunospot, Cell Culture, Positive Control, Binding Assay, Comparison

Review

Structured Review

Images

Similar Products

Image Search Results